mouse monoclonal cd8a  (fluidigm)

Journal: Oncoimmunology

Article Title: Prostate tumor immune microenvironment changes following immunotherapy shared by patients who developed anti-tumor response or immune-related adverse events

doi: 10.1080/2162402X.2025.2595788

Figure Lengend Snippet: CD8 T cell-rich zones were present in both pre- and post-treatment tumor biopsies. Patient biopsies were collected at 0 weeks (baseline, pre-treatment) and at 12 weeks (post-treatment) and stored as FFPE blocks. Tissue sections (5 µm thick) were obtained and processed for either nCounter (A) or GeoMx analysis (B-D). The whole section was digested to extract RNA and processed following the nCounter workflow, whereas CD8 T cell rich or excluded regions were selected for processing through the GeoMx workflow. Volcano plots resulting from the differential expression analysis are presented here. Gene expression levels between pre- and post-treatment samples were compared using nCounter (A). Protein expression levels in CD8 T cell-rich ROIs between pre- and post-treatment samples were compared using GeoMx (B), and protein expression levels in CD8 T cell-rich regions were Compared to CD8 T cell excluded regions using pre-treatment biopsy samples (C) or in post-treatment biopsy samples using GeoMx (D). The arrows highlight the genes discussed related to the nCounter analysis. p < 0.05 as represented by log 10 ( p -value) >1.3 was considered to be statistically significant and is marked by dashed and dotted green lines in all plots. Fold change of >2 or <–2, as represented by log2(fold change) >1 or <–1 were considered significant changes in expression and are marked by dashed red lines in each plot.

Article Snippet: An anti-human CD8a (Clone ID: OTI3H6) monoclonal antibody (Cat# CF802079 ) was purchased from Origene and conjugated with AF647 using Alexa Fluor 647 antibody labeling kit (Cat# A20186 , Thermo Fisher Scientific) following the manufacturer’s protocol.

Techniques: Quantitative Proteomics, Gene Expression, Expressing

Journal: Oncoimmunology

Article Title: Prostate tumor immune microenvironment changes following immunotherapy shared by patients who developed anti-tumor response or immune-related adverse events

doi: 10.1080/2162402X.2025.2595788

Figure Lengend Snippet: Markers associated with dendritic cells and antigen presentation were associated with the clinical response. Patient biopsies collected pre- and post-treatment were processed as described in . Volcano plots resulting from the differential expression analysis are presented here. Gene expression levels between responders and non-responders were compared using nCounter within pre-treatment biopsy samples (A) or in post-treatment biopsy samples (B). Protein expression levels between responders and non-responders were compared within post-treatment biopsy samples using GeoMx (C), and protein expression levels in CD8 T cell rich regions were compared between responders and non-responders using both pre- and post-treatment biopsy samples (D). The arrows highlight the genes discussed related to the nCounter analysis. p < 0.05 as represented by log 10 ( p -value) >1.3 was considered to be statistically significant and is marked by dashed and dotted green lines in all plots. Fold change of >2 or <−2 as represented by log2(fold change) >1 or <−1 was considered to be a significant change in expression and is marked by dashed red lines in each plot.

Article Snippet: An anti-human CD8a (Clone ID: OTI3H6) monoclonal antibody (Cat# CF802079 ) was purchased from Origene and conjugated with AF647 using Alexa Fluor 647 antibody labeling kit (Cat# A20186 , Thermo Fisher Scientific) following the manufacturer’s protocol.

Techniques: Immunopeptidomics, Quantitative Proteomics, Gene Expression, Expressing

Journal: Oncoimmunology

Article Title: Prostate tumor immune microenvironment changes following immunotherapy shared by patients who developed anti-tumor response or immune-related adverse events

doi: 10.1080/2162402X.2025.2595788

Figure Lengend Snippet: Patients who developed irAEs showed increased T cell activation; whereas PARP expression was elevated in patients that did not develop an irAE. Patient biopsies collected pre- and post-treatment were processed as described in . Volcano plots resulting from the differential expression analysis are presented here. Gene expression levels between patients who experienced an irAE or did not experience irAEs were compared using nCounter within post-treatment biopsy samples (A). Protein expression levels between patients who experienced an irAE or did not experience an irAE were compared within post-treatment biopsy samples using GeoMx (B), and protein expression levels in CD8 T cell rich regions were compared between patients who experienced an irAE or did not experience an irAE within post-treatment biopsy samples (C). The arrows highlight the genes discussed related to the nCounter analysis. p < 0.05 as represented by log 10 ( p -value) >1.3 was considered to be statistically significant and is marked by dashed and dotted green lines in all plots. Fold change of >2 or <−2, as represented by log2(fold change) >1 or <–1 were considered to be a significant change in expression and are marked by dashed red lines in each plot.

Article Snippet: An anti-human CD8a (Clone ID: OTI3H6) monoclonal antibody (Cat# CF802079 ) was purchased from Origene and conjugated with AF647 using Alexa Fluor 647 antibody labeling kit (Cat# A20186 , Thermo Fisher Scientific) following the manufacturer’s protocol.

Techniques: Activation Assay, Expressing, Quantitative Proteomics, Gene Expression

Journal: eLife

Article Title: JAK inhibition decreases the autoimmune burden in Down syndrome

doi: 10.7554/eLife.99323

Figure Lengend Snippet:

Article Snippet: Antibody , Mouse monoclonal anti-human CD8a (clone RPA-T8) , Fluidigm , Cat # 3162015; RRID: AB_2661802 , Lot 0171813, 1:100.

Techniques: Isolation, Biomarker Discovery, Staining, Antibody Labeling, Software, Sequencing

Journal: The Journal of Clinical Investigation

Article Title: Viral infection induces inflammatory signals that coordinate YAP regulation of dysplastic cells in lung alveoli

doi: 10.1172/JCI176828

Figure Lengend Snippet: ( A and B ) Illustration of IAV- and bleomycin-induced lung injury models. Sac, sacrifice. ( C and D ) Immunofluorescence staining for KRT5 and SCGB1A1 in IAV- and bleomycin-injured lungs. Data are representative of sections from 3 mice. Scale bars: 500 μm (top row); 50 μm (bottom row). ( E and F ) Immunofluorescence images of dysplastic cells (KRT5 + PDPN + ) and AT1 (PDPN + ) cells. Scale bars: 500 μm (top row); 50 μm (bottom row). ( G ) Quantification of percentages of KRT5 + lung areas in total damaged alveolar areas (PDPN – and KRT5 + ) in IAV- and bleomycin-injured lungs ( n ≥ 4 mice per group). ( H ) Krt5 expression was assayed by qRT-PCR in IAV- and bleomycin-injured lungs ( n = 3 mice per group). ( I and J ) PAS staining and quantification of goblet cells in IAV- and bleomycin-injured lungs ( n = 5 mice per group). Scale bar: 50 μm. ( K ) Inflammatory factor mRNA expression was assayed by qRT-PCR in IAV- and bleomycin-injured lungs at indicated time points ( n = 3 mice per group). ( L ) Flow cytometry analysis of immune cells from PBS-, repetitive bleomycin–, or IAV-treated lungs at indicated time points ( n = 4 mice per group). ( M ) Immunofluorescence staining for CD4, CD8a, F4/80, CCR2, or NK1.1 with KRT5 in IAV- and bleomycin-injured lungs at 14 dpi. Data are representative of sections from 3 mice. Scale bar: 50 μm. * P < 0.05; ** P < 0.01; *** P < 0.001. Error bars represent means ± SEM. Multiple t tests ( H , K , and L ); 2-tailed Mann-Whitney U test ( G and J ).

Article Snippet: The following primary antibodies were used at the indicated concentrations for immunofluorescence staining: goat anti-SCGB3A2 polyclonal antibody (5 μg/mL) (R&D Systems, AF3465), rat anti-ITGB4 monoclonal antibody (5 μg/mL) (BioLegend, 123615), rat anti-F4/80 monoclonal antibody (5 μg/mL) (BioLegend, 111603), rabbit anti-CCR2 monoclonal antibody (5 μg/mL) (Abcam, ab216863), rabbit anti-KRT5 polyclonal antibody (5 μg/mL) (BioLegend, 905504), chicken anti-KRT5 polyclonal antibody (5 μg/mL) (BioLegend, 905903), mouse anti-SCGB1A1 monoclonal antibody (5 μg/mL) (Santa Cruz Biotechnology Inc., sc-365992), rabbit anti-CCSP polyclonal antibody (5 μg/mL) (Seven Hills, WRAB-3950), mouse anti-FOXJ1 monoclonal antibody (5 μg/mL) (Invitrogen, 14-9965-82), hamster anti-PDPN monoclonal antibody (5 μg/mL) (Invitrogen, 14-5381-82), rat anti-CD4 monoclonal antibody (5 μg/mL) (BioLegend, 100427), rat anti-CD8a monoclonal antibody (5 μg/mL) (BioLegend, 100707), mouse anti-NK1.1 monoclonal antibody (5 μg/mL) (BioLegend, 108729), rabbit anti-DCAMKL1 polyclonal antibody (5 μg/mL) (Abcam, ab31704), rabbit anti-proSPC polyclonal antibody (5 μg/mL) (MilliporeSigma, AB3786), rabbit anti-phospho-Src(Tyr416) polyclonal antibody (5 μg/mL) (Cell Signaling Technology, 2101S), rabbit anti-YAP polyclonal antibody (5 μg/mL) (Cell Signaling Technology, 4912S), mouse anti-KI67 monoclonal antibody(5 μg/mL) (BioLegend, 151204), rabbit anti-KI67 monoclonal antibody (5 μg/mL) (Cell Signaling Technology, 9129S), mouse anti-P63 monoclonal antibody (5 μg/mL) (Abcam, ab735), mouse anti-KRT17 monoclonal antibody (5 μg/mL) (Santa Cruz Biotechnology Inc., sc-393002), rat anti-KRT8 polyclonal antibody (5 μg/mL) (DSHB, Troma-1), mouse anti-human HTII-280 (5 μg/mL) (Terrace Biotech, TB-27AHT2-280), and mouse anti-human CD8a monoclonal antibody (5 μg/mL) (Invitrogen, 12-0088-42).

Techniques: Immunofluorescence, Staining, Expressing, Quantitative RT-PCR, Flow Cytometry, MANN-WHITNEY

Journal: The Journal of Clinical Investigation

Article Title: Viral infection induces inflammatory signals that coordinate YAP regulation of dysplastic cells in lung alveoli

doi: 10.1172/JCI176828

Figure Lengend Snippet: ( A ) H&E staining and immunofluorescence staining for CD8a, p-SRC, YAP, and KRT5 on lung sections from COVID-19 patients. Scale bar: 50 μm. ( B ) Illustration of human AT2 organoid culture experiment. ( C – F ) Bright-field and immunofluorescence images of human AT2 organoids treated with PBS, IFN-γ, IFN-γ and Src inhibitor (dasatinib), or IFN-γ and FAK inhibitor (PF-573228). Scale bar: 25 μm. ( G – L ) Quantification of percentages of HTII-280–, SFTPC-, KRT8-, KRT17-, and KRT5-expressing organoids in total human AT2 organoids treated with PBS, IFN-γ, IFN-γ and Src inhibitor (dasatinib), or IFN-γ and FAK inhibitor (PF-573228) ( n = 3 technical replicates, experiment repeated twice). * P < 0.05; ** P < 0.01; *** P < 0.001. Error bars represent means ± SEM. One-way ANOVA ( G – L ).

Article Snippet: The following primary antibodies were used at the indicated concentrations for immunofluorescence staining: goat anti-SCGB3A2 polyclonal antibody (5 μg/mL) (R&D Systems, AF3465), rat anti-ITGB4 monoclonal antibody (5 μg/mL) (BioLegend, 123615), rat anti-F4/80 monoclonal antibody (5 μg/mL) (BioLegend, 111603), rabbit anti-CCR2 monoclonal antibody (5 μg/mL) (Abcam, ab216863), rabbit anti-KRT5 polyclonal antibody (5 μg/mL) (BioLegend, 905504), chicken anti-KRT5 polyclonal antibody (5 μg/mL) (BioLegend, 905903), mouse anti-SCGB1A1 monoclonal antibody (5 μg/mL) (Santa Cruz Biotechnology Inc., sc-365992), rabbit anti-CCSP polyclonal antibody (5 μg/mL) (Seven Hills, WRAB-3950), mouse anti-FOXJ1 monoclonal antibody (5 μg/mL) (Invitrogen, 14-9965-82), hamster anti-PDPN monoclonal antibody (5 μg/mL) (Invitrogen, 14-5381-82), rat anti-CD4 monoclonal antibody (5 μg/mL) (BioLegend, 100427), rat anti-CD8a monoclonal antibody (5 μg/mL) (BioLegend, 100707), mouse anti-NK1.1 monoclonal antibody (5 μg/mL) (BioLegend, 108729), rabbit anti-DCAMKL1 polyclonal antibody (5 μg/mL) (Abcam, ab31704), rabbit anti-proSPC polyclonal antibody (5 μg/mL) (MilliporeSigma, AB3786), rabbit anti-phospho-Src(Tyr416) polyclonal antibody (5 μg/mL) (Cell Signaling Technology, 2101S), rabbit anti-YAP polyclonal antibody (5 μg/mL) (Cell Signaling Technology, 4912S), mouse anti-KI67 monoclonal antibody(5 μg/mL) (BioLegend, 151204), rabbit anti-KI67 monoclonal antibody (5 μg/mL) (Cell Signaling Technology, 9129S), mouse anti-P63 monoclonal antibody (5 μg/mL) (Abcam, ab735), mouse anti-KRT17 monoclonal antibody (5 μg/mL) (Santa Cruz Biotechnology Inc., sc-393002), rat anti-KRT8 polyclonal antibody (5 μg/mL) (DSHB, Troma-1), mouse anti-human HTII-280 (5 μg/mL) (Terrace Biotech, TB-27AHT2-280), and mouse anti-human CD8a monoclonal antibody (5 μg/mL) (Invitrogen, 12-0088-42).

Techniques: Staining, Immunofluorescence, Expressing

Journal: Cancer Management and Research

Article Title: Distribution of CD8 T Cells and NK Cells in the Stroma in Relation to Recurrence or Metastasis of Nasopharyngeal Carcinoma

doi: 10.2147/CMAR.S365230

Figure Lengend Snippet: CIBERSORT algorithm was used to evaluate the microenvironment of 30 NPC samples and 22 normal nasopharyngeal sample in GEO cohort. ( A ). The proportions of TIICs in samples vary significantly between both intragroup and intergroup. ( B ). T cells, macrophages account for most of the TIICs in NPC microenvironment. ( C ). Different kinds of TIICs in NPC correlate with each other. ( D ). The violin plot suggested that plasma cell, CD8 T cells, activated NK cells, macrophage M0 and macrophage M1 were highly expressed in NPC tissues.

Article Snippet: These TIICs were stained with different antibodies as follows: an anti-human CD8 mouse monoclonal antibody (TA802079S, dilution 1:150, Origene), an anti-human CD56 mouse monoclonal antibody (TA805376S, dilution 1:150, Origene), an anti-human CD68 mouse monoclonal antibody (TA802949S, dilution 1:500, Origene), and an anti-human CD138 mouse monoclonal antibody (TA813799S, dilution 1:1000, Origene).

Techniques: Clinical Proteomics

Journal: Cancer Management and Research

Article Title: Distribution of CD8 T Cells and NK Cells in the Stroma in Relation to Recurrence or Metastasis of Nasopharyngeal Carcinoma

doi: 10.2147/CMAR.S365230

Figure Lengend Snippet: CD8 T cells, NK cell, macrophages, and plasma cell were stained in tumor core and stromal in NPC by immunohistochemistry. ( A ). CD8 200× ( B ). CD8 400× ( C ). CD56 200× ( D ). CD56 400× ( E ). CD68 200× ( F ). CD68 400× ( G ). CD138 200× ( H ). CD138 400×.

Article Snippet: These TIICs were stained with different antibodies as follows: an anti-human CD8 mouse monoclonal antibody (TA802079S, dilution 1:150, Origene), an anti-human CD56 mouse monoclonal antibody (TA805376S, dilution 1:150, Origene), an anti-human CD68 mouse monoclonal antibody (TA802949S, dilution 1:500, Origene), and an anti-human CD138 mouse monoclonal antibody (TA813799S, dilution 1:1000, Origene).

Techniques: Clinical Proteomics, Staining, Immunohistochemistry

Journal: Cancer Management and Research

Article Title: Distribution of CD8 T Cells and NK Cells in the Stroma in Relation to Recurrence or Metastasis of Nasopharyngeal Carcinoma

doi: 10.2147/CMAR.S365230

Figure Lengend Snippet: Differential analysis of CD8 T cells, NK cells, macrophages and plasma cell expression in tumor core and stroma. ( A – C ). CD8 T cells, NK cells, macrophages were significantly more abundant in the stroma. ( D ). plasma cell had more abundant in tumor core.

Article Snippet: These TIICs were stained with different antibodies as follows: an anti-human CD8 mouse monoclonal antibody (TA802079S, dilution 1:150, Origene), an anti-human CD56 mouse monoclonal antibody (TA805376S, dilution 1:150, Origene), an anti-human CD68 mouse monoclonal antibody (TA802949S, dilution 1:500, Origene), and an anti-human CD138 mouse monoclonal antibody (TA813799S, dilution 1:1000, Origene).

Techniques: Clinical Proteomics, Expressing

Journal: Cancer Management and Research

Article Title: Distribution of CD8 T Cells and NK Cells in the Stroma in Relation to Recurrence or Metastasis of Nasopharyngeal Carcinoma

doi: 10.2147/CMAR.S365230

Figure Lengend Snippet: Differential analysis of CD8 T cells, NK cells, macrophages and plasma cell expression in recurrence or metastasis group and no recurrence or metastasis group. ( A and B ). CD8 T cells and NK cell in recurrence or metastasis group were significantly higher. ( C and D ). macrophages and plasma cell were not statistically different between the two groups.

Article Snippet: These TIICs were stained with different antibodies as follows: an anti-human CD8 mouse monoclonal antibody (TA802079S, dilution 1:150, Origene), an anti-human CD56 mouse monoclonal antibody (TA805376S, dilution 1:150, Origene), an anti-human CD68 mouse monoclonal antibody (TA802949S, dilution 1:500, Origene), and an anti-human CD138 mouse monoclonal antibody (TA813799S, dilution 1:1000, Origene).

Techniques: Clinical Proteomics, Expressing

Journal: Cancer Management and Research

Article Title: Distribution of CD8 T Cells and NK Cells in the Stroma in Relation to Recurrence or Metastasis of Nasopharyngeal Carcinoma

doi: 10.2147/CMAR.S365230

Figure Lengend Snippet: Survival analysis of CD8 T cells, NK cell, macrophages and plasma cell. ( A and B ) The abundance of CD8 T cells and NK cell were significantly correlated with favorable prognosis of NPC. ( C and D ) The abundance of macrophages and plasma cell were not associated with patient survival.

Article Snippet: These TIICs were stained with different antibodies as follows: an anti-human CD8 mouse monoclonal antibody (TA802079S, dilution 1:150, Origene), an anti-human CD56 mouse monoclonal antibody (TA805376S, dilution 1:150, Origene), an anti-human CD68 mouse monoclonal antibody (TA802949S, dilution 1:500, Origene), and an anti-human CD138 mouse monoclonal antibody (TA813799S, dilution 1:1000, Origene).

Techniques: Clinical Proteomics

Journal: Cancer Management and Research

Article Title: Distribution of CD8 T Cells and NK Cells in the Stroma in Relation to Recurrence or Metastasis of Nasopharyngeal Carcinoma

doi: 10.2147/CMAR.S365230

Figure Lengend Snippet: Kaplan–Meier analysis were applied to evaluate the recurrence or metastasis value of CD8 T cells, NK cells, macrophages and plasma cell. ( A and B ) The abundance of CD8 T cells and NK cell were significantly correlated with favorable RMFS of NPC. ( C and D ) The abundance of macrophages and plasma cell had no significant correction with RMFS.

Article Snippet: These TIICs were stained with different antibodies as follows: an anti-human CD8 mouse monoclonal antibody (TA802079S, dilution 1:150, Origene), an anti-human CD56 mouse monoclonal antibody (TA805376S, dilution 1:150, Origene), an anti-human CD68 mouse monoclonal antibody (TA802949S, dilution 1:500, Origene), and an anti-human CD138 mouse monoclonal antibody (TA813799S, dilution 1:1000, Origene).

Techniques: Clinical Proteomics

Journal: Cancer Management and Research

Article Title: Distribution of CD8 T Cells and NK Cells in the Stroma in Relation to Recurrence or Metastasis of Nasopharyngeal Carcinoma

doi: 10.2147/CMAR.S365230

Figure Lengend Snippet: The expression of CD8 T cells and NK cell were significantly correlated with RMFS in both univariate and multivariate cox regression. ( A ). T, age, CD8 T cells and NK cell showed significant correlation to RMFS of NPC. ( B ). CD8 T cells and NK cell expression were independent influence factor for RMFS of NPC.

Article Snippet: These TIICs were stained with different antibodies as follows: an anti-human CD8 mouse monoclonal antibody (TA802079S, dilution 1:150, Origene), an anti-human CD56 mouse monoclonal antibody (TA805376S, dilution 1:150, Origene), an anti-human CD68 mouse monoclonal antibody (TA802949S, dilution 1:500, Origene), and an anti-human CD138 mouse monoclonal antibody (TA813799S, dilution 1:1000, Origene).

Techniques: Expressing